BR0116526A - Compostos derivados do diidronaftaleno e agentes compreendendo o derivado como componente ativo - Google Patents

Compostos derivados do diidronaftaleno e agentes compreendendo o derivado como componente ativo

Info

Publication number
BR0116526A
BR0116526A BR0116526-7A BR0116526A BR0116526A BR 0116526 A BR0116526 A BR 0116526A BR 0116526 A BR0116526 A BR 0116526A BR 0116526 A BR0116526 A BR 0116526A
Authority
BR
Brazil
Prior art keywords
agents
compounds
derivative
active component
diabetes
Prior art date
Application number
BR0116526-7A
Other languages
English (en)
Inventor
Hisao Tajima
Yoshisuke Nakayama
Daikichi Fukushima
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BR0116526A publication Critical patent/BR0116526A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"COMPOSTOS DERIVADOS DO DIIDRONAFTALENO E AGENTES COMPREENDENDO O DERIVADO COMO COMPONENTE ATIVO". Compostos representados pela seguinte fórmula geral (I) : (I) onde cada símbolo apresenta o significado conforme definido na descrição: sais destes e drogas para controlar o receptor ativado pela proliferação da peroxisoma que contém estes compostos como componente ativo. Em virtude de apresentar uma atividade de controle do receptor ativado pela proliferação do peroxisoma, os compostos de fórmula geral (I) são úteis como hipoglicêmicos, agentes redutores de gorduras, conservantes e/ou medicamentos para erros metabólicos, tais como diabetes, obesidade, síndrome X, hiprcolesterolemia e hiperlipoproteinemia, conservantes e/ou medicamentos para hiperglicemia, arteriosclerose, hipertensão, doenças circulatórias, comer demasiadamente, doenças cardíacas isquêmicas, etc., agentes elevadores do colesterol HDL, agentes redutores do colesterol VLDL e/ou LDL e agentes de alívio do fator de risco para diabetes e síndrome X.
BR0116526-7A 2000-12-25 2001-12-21 Compostos derivados do diidronaftaleno e agentes compreendendo o derivado como componente ativo BR0116526A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000392723 2000-12-25
PCT/JP2001/011255 WO2002051820A1 (fr) 2000-12-25 2001-12-21 Composes derives de dihydronaphtalene et medicaments utilisant ces composes comme ingredient actif

Publications (1)

Publication Number Publication Date
BR0116526A true BR0116526A (pt) 2004-07-06

Family

ID=18858667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116526-7A BR0116526A (pt) 2000-12-25 2001-12-21 Compostos derivados do diidronaftaleno e agentes compreendendo o derivado como componente ativo

Country Status (23)

Country Link
US (2) US7220864B2 (pt)
EP (2) EP1726586A1 (pt)
JP (1) JP3491635B2 (pt)
KR (2) KR100718906B1 (pt)
CN (1) CN100357280C (pt)
AT (1) ATE370130T1 (pt)
BR (1) BR0116526A (pt)
CA (1) CA2432211C (pt)
CZ (1) CZ20031772A3 (pt)
DE (1) DE60130031T2 (pt)
DK (1) DK1354879T3 (pt)
ES (1) ES2291378T3 (pt)
HU (1) HUP0303636A3 (pt)
IL (2) IL156505A0 (pt)
MX (1) MXPA03005763A (pt)
NO (1) NO327132B1 (pt)
NZ (1) NZ526687A (pt)
PL (1) PL207798B1 (pt)
PT (1) PT1354879E (pt)
RU (1) RU2268262C2 (pt)
TW (1) TWI235748B (pt)
WO (1) WO2002051820A1 (pt)
ZA (1) ZA200304913B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
DE10308351A1 (de) * 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308354A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1741704A1 (en) * 2004-04-20 2007-01-10 Ono Pharmaceutical Co., Ltd. Method for increasing specific surface area of slightly soluble drug
AU2006311523A1 (en) * 2005-11-07 2007-05-18 Irm Llc Oxazole and thiazole PPAR modulator
JP5718233B2 (ja) 2008-10-20 2015-05-13 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト
WO2011127388A2 (en) 2010-04-08 2011-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inverse agonists and neutral antagonists for the tsh receptor
WO2012027482A2 (en) * 2010-08-24 2012-03-01 Georgetown University Compounds, compositions and methods related to ppar antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes

Also Published As

Publication number Publication date
IL156505A0 (en) 2004-01-04
CA2432211A1 (en) 2002-07-04
MXPA03005763A (es) 2004-05-03
NZ526687A (en) 2004-08-27
EP1354879A1 (en) 2003-10-22
PL207798B1 (pl) 2011-02-28
PL363583A1 (en) 2004-11-29
HUP0303636A3 (en) 2006-02-28
EP1354879A4 (en) 2004-09-22
NO327132B1 (no) 2009-04-27
KR100718906B1 (ko) 2007-05-18
US20040138213A1 (en) 2004-07-15
NO20032895L (no) 2003-08-25
CN100357280C (zh) 2007-12-26
EP1726586A1 (en) 2006-11-29
ATE370130T1 (de) 2007-09-15
KR20060083436A (ko) 2006-07-20
JPWO2002051820A1 (ja) 2004-04-22
DE60130031D1 (de) 2007-09-27
CZ20031772A3 (cs) 2003-11-12
DE60130031T2 (de) 2008-05-15
ZA200304913B (en) 2004-01-22
KR100635315B1 (ko) 2006-10-18
ES2291378T3 (es) 2008-03-01
PT1354879E (pt) 2007-10-29
JP3491635B2 (ja) 2004-01-26
RU2268262C2 (ru) 2006-01-20
EP1354879B1 (en) 2007-08-15
CN1489582A (zh) 2004-04-14
KR20030064871A (ko) 2003-08-02
US7220864B2 (en) 2007-05-22
HUP0303636A2 (hu) 2004-03-01
WO2002051820A1 (fr) 2002-07-04
DK1354879T3 (da) 2007-12-17
NO20032895D0 (no) 2003-06-23
US20060287304A1 (en) 2006-12-21
TWI235748B (en) 2005-07-11
IL156505A (en) 2009-09-22
CA2432211C (en) 2010-07-13

Similar Documents

Publication Publication Date Title
BR0116526A (pt) Compostos derivados do diidronaftaleno e agentes compreendendo o derivado como componente ativo
Zieve et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes
Hamilton et al. Tolerability and compliance with risedronate in clinical practice
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
BR0212512A (pt) Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
Mesotten et al. Glycemic targets and approaches to management of the patient with critical illness
Franek et al. Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naive adults with Type 2 diabetes
BRPI0211665B8 (pt) "composto de pirrol substituído"
BRPI0513840A (pt) método para controle de obesidade em um paciente mamìfero necessitado de um tal tratamento, método para tratamento de obesidade em um paciente humano diabético e sendo tratado com uma droga receitada para diabetes, método para tratamento de diabetes mellitus em um paciente mamìfero necessitado de um tal tratamento para controle da diabetes mellitus, método para tratamento ou controle de hiperglicemia em um paciente mamìfero necessitado de um tal tratamento, composição para uso no tratamento de obesidade, diabetes, ou hiperglicemia como doença, método para tratamento ou controle de distúrbios lipìdicos, hiperlipidemia, ou baixo nìvel de hdl em um paciente mamìfero necessitado do mesmo, método para tratamento ou controle de hipercolesterolemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de hipergligeridemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de dislipidemia e/ou baixo nìvel de hdl colesterol em um paciente mamìfero necessitado de um tal tratamento, e método para tratamento de arteriosclerose em um paciente mamìfero necessitado de um tal tratamento
Melkersson et al. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism
EP1122255A4 (en) CARBONIC ACID DERIVATIVES AND MEDICINES THAT CONTAIN THEM AS ACTIVE INGREDIENTS
Davies et al. Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial
BR0016131A (pt) Forma cristalina, formulação farmacêutica, uso de uma forma cristalina, uso de uma substância, métodos para tratamento ou a profilaxia de, condições associadas com reduzida sensibilidade à insulina, e de deslipidemia, diabetes melito do tipo 2, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal, e , processo para a preparação de uma forma cristalina de um composto de fórmula i
Moppett et al. The effect of intravenous iron on erythropoiesis in older people with hip fracture
BR9913746A (pt) Composto da série de piridìnio, processo para prepará-lo, uso do mesmo, composição farmacêutica para o tratamento de complicações diabéticas e doenças relacionadas ao envelhecimento, e, métodos para a preparação de uma formulação parenteral, para tratar um paciente diabético pela ruptura de age preformado dentro do referido paciente, e para evitar ou tratar doenças causadas por diabetes e complicações relacionadas ao envelhecimento
Bangsberg Monitoring adherence to HIV antiretroviral therapy in routine clinical practice: the past, the present, and the future
BR0016135A (pt) Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto
Kumar et al. Clinical use of the co‐formulation of insulin degludec and insulin aspart
EP1108713A4 (en) CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE COMPONENT
Evangelatos et al. Zoledronic acid in nine patients with transient osteoporosis of the hip
BRPI0408325A (pt) compostos derivados de imino éter e medicamentos contendo os compostos como o ingrediente ativo
Mao et al. Severe anion gap acidosis associated with intravenous sodium thiosulfate administration
NO20050398L (no) Nye adenosinanaloger og deres anvendelse som farmasoytiske midler
BR0214049A (pt) Compostos derivados de ácido carboxìlico e drogas contendo o mesmo como ingrediente ativo

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.